Healthcare >> CEO Interviews >> December 8, 1997
KENNETH M. COHEN is President and Chief Executive Officer of Synbiotics
Corporation, which he joined in May, 1996. Previously, Mr. Cohen was
Executive Vice President and Chief Operating Officer for Canji
Incorporated, a leading gene-therapy company, until its acquisition by
Schering-Plough Corporation in February 1996. Prior to joining Canji,
Mr. Cohen was Vice President of Business Affairs at Argus
Pharmaceuticals, Inc. (now known as Aronex Pharmaceuticals), and Vice
President for Marketing and Business Development for LifeCell
Corporation. Mr. Cohen also served in various position of increasing
responsibility during 10 years at Eli Lilly and Company, Inc., including
Director of Business Planning for the medical instrument systems
division (now known as Guidant Corp.) and marketing manager responsible
for the launch of Prozac_. Mr. Cohen received an A.B. in biology and
chemistry from Dartmouth College in 1976 and his M.B.A. in 1978 from the
Wharton School. Profile
what is the company doing today?
Mr. Cohen: Synbiotics started up about 15 years ago, originally as a
biotechnology
